KOL Knockout™: Cataract Edition —Maximizing the Use of Aberrometry, Femtosecond Lasers, and Advanced IOLs to Improve Postoperative Outcomes in Cataract Surgery - Final Round

This activity is supported by an independent educational grant from Alcon Vision.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Summarize the technology of femtosecond laser-assisted cataract surgery
• Explain how to incorporate femtosecond laser technology into cataract surgery techniques.
• Establish when to incorporate intraoperative aberrometry to provide better refractive outcomes for cataract patients.
• Evaluate patient lifestyles and expectations to improve intraocular lens choice.

• Compare current and emerging technologies in advanced technology intraocular lenses

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.   Credit Designation Statement Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Uday Devgan, MD, FACS, FRCS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker: Bausch & Lomb and Novartis; Shareholder: Advanced Euclidean Solutions, CataractCoach.com, and LensGen.

David A. Goldman, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, and Novartis. Speaker's Bureau: Allergan, and Eyevance. Stock/Shareholder: Alcon, Allergan, Johnson & Johnson, Kala Pharmaceuticals, Ocular Therapeutix, Stroma, and Tarsus.

John A. Hovanesian, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: 1-800-Doctors, Aerie Pharmaceuticals, Abbott Medical Optics, Blephex, Cord, Eyedetec, Glaukos, Guardian Health Sciences, Ingenoeye, IOP/Katena, Ivantis, Kala, MDBackline, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Sight Sciences, Tearlab,  Tearfilm Innovations, Valeant, and Veracity. Consultant:  1-800-Doctors, Acufocus, Aerie Pharmaceuticals, Alcon Vision, Allegro Ophthalmics, Allergan, Abbott Medical Optics, BlephEx,  Eyedetec, Glaukos, Guardian Health Sciences, IOP/Katena, Ivantis, Kala, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Sarentis ophthalmics, Sensimed, Shire, Tearlab, Tearfilm Innovations, Valeant, and Veracity. Grant/Research: Aerie Pharmaceuticals, Abbott Medical Optics, Alcon Vision, Allergan, Cloudbreak Therapeutics, Cord, Eydetec, Glaukos, Ingenoeye, IOP/Katena, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Tearfilm Innovations, and Valeant. Stock/Shareholder/Equity: Alcon Vision, Alicia Surgery Center, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardian Health Sciences, Harvard Eye Associates, Harvard Hearing, Ingenoeye, MDBackline, Novartis, Ocular Therapeutix, RxSight, Sarentis Ophthalmics, Sight Sciences, and Tearfilm Innovations. Royalties: SlackBooks and TLC: The Laser Center.

Denise M. Visco, MD, MBA,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bruder, Cassini, LENSAR, Omeros, Sun Ophthalmic, Zeiss, Inc. Grant/Research Support: LENSAR, Oyster Point Pharma. LENSAR, Omeros, Sun Ophthalmic, Zeiss, Inc. Speaker’s Bureau: LENSAR, Omeros, Sun Ophthalmic, Zeiss, Inc. Stock/Shareholder: Eyevance.

 

The Evolve staff, planners and peer reviewer have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Alcon Vision.